NCT05652686 2025-09-23
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
Phase 1/2 Recruiting
Phanes Therapeutics
Shanghai Chest Hospital
The First Affiliated Hospital with Nanjing Medical University
Beijing Tiantan Hospital